Molecular structure of Odanacatib, CAS Number: 603139-19-1
Odanacatib (CAS 603139-19-1)
See product citations (2)
Alternate Names:
Odanacatib is also known as MK-0822.
Application:
Odanacatib is a neutral cathepsin K inhibitor with anti-osteoporotic and anti-resorptive activities.
CAS Number:
603139-19-1
Purity:
≥98%
Molecular Weight:
525.59
Molecular Formula:
C25H27F4N3O3S
Supplemental Information:
This is classified as a Dangerous Good for transport and may be subject to additional shipping charges.
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.
* Refer to Certificate of Analysis for lot specific data.
QUICK LINKS
Ordering Information
Product Citations
Description
Technical Information
Safety Information
SDS & Certificate of Analysis
Odanacatib, a powerful and specific inhibitor of cathepsin K, effectively inhibits the enzymatic activity of cathepsin K with high potency (IC50s = 0.2 and 1 nM for human and rabbit enzymes, respectively). Cathepsin K is a protease responsible for osteoclastic bone resorption. Notably, odanacatib exhibits remarkable selectivity for cathepsin K over cathepsins B, L, and S. When formulated, odanacatib effectively decreases bone resorption while causing only modest reductions in bone formation. Consequently, this leads to an increase in bone mineral density.
Odanacatib (CAS 603139-19-1) References
- Pharmacokinetics and metabolism in rats, dogs, and monkeys of the cathepsin k inhibitor odanacatib: demethylation of a methylsulfonyl moiety as a major metabolic pathway. | Kassahun, K., et al. 2011. Drug Metab Dispos. 39: 1079-87. PMID: 21422190
- Osteoporosis: now and the future. | Rachner, TD., et al. 2011. Lancet. 377: 1276-87. PMID: 21450337
- Odanacatib reduces bone turnover and increases bone mass in the lumbar spine of skeletally mature ovariectomized rhesus monkeys. | Masarachia, PJ., et al. 2012. J Bone Miner Res. 27: 509-23. PMID: 22113859
- Odanacatib treatment increases hip bone mass and cortical thickness by preserving endocortical bone formation and stimulating periosteal bone formation in the ovariectomized adult rhesus monkey. | Cusick, T., et al. 2012. J Bone Miner Res. 27: 524-37. PMID: 22113921
- Effects of Odanacatib on bone mineralization density distribution in thoracic spine and femora of ovariectomized adult rhesus monkeys: a quantitative backscattered electron imaging study. | Fratzl-Zelman, N., et al. 2013. Calcif Tissue Int. 92: 261-9. PMID: 23179105
- The bone resorption inhibitors odanacatib and alendronate affect post-osteoclastic events differently in ovariectomized rabbits. | Jensen, PR., et al. 2014. Calcif Tissue Int. 94: 212-22. PMID: 24085265
- Development and validation of an RP-HPLC method for the quantitation of odanacatib in rat and human plasma and its application to a pharmacokinetic study. | Police, A., et al. 2015. Biomed Chromatogr. 29: 1664-9. PMID: 25914381
- Odanacatib increases mineralized callus during fracture healing in a rabbit ulnar osteotomy model. | Pennypacker, BL., et al. 2016. J Orthop Res. 34: 72-80. PMID: 26178170
- Odanacatib Restores Trabecular Bone of Skeletally Mature Female Rabbits With Osteopenia but Induces Brittleness of Cortical Bone: A Comparative Study of the Investigational Drug With PTH, Estrogen, and Alendronate. | Khan, MP., et al. 2016. J Bone Miner Res. 31: 615-29. PMID: 26391310
- Effects of Long-Term Odanacatib Treatment on Bone Gene Expression in Ovariectomized Adult Rhesus Monkeys: Differentiation From Alendronate. | Muise, ES., et al. 2016. J Bone Miner Res. 31: 839-51. PMID: 26587671
- Odanacatib, effects of 16-month treatment and discontinuation of therapy on bone mass, turnover and strength in the ovariectomized rabbit model of osteopenia. | Duong, LT., et al. 2016. Bone. 93: 86-96. PMID: 27639811
- Effects of odanacatib on bone matrix mineralization in rhesus monkeys are similar to those of alendronate. | Misof, BM., et al. 2016. Bone Rep. 5: 62-69. PMID: 28326348
- Long-term treatment with odanacatib maintains normal trabecular biomechanical properties in ovariectomized adult monkeys as demonstrated by micro-CT-based finite element analysis. | Cabal, A., et al. 2017. Bone Rep. 6: 26-33. PMID: 28377978
- Differing Effects of Parathyroid Hormone, Alendronate, and Odanacatib on Bone Formation and on the Mineralization Process in Intracortical and Endocortical Bone of Ovariectomized Rabbits. | Vrahnas, C., et al. 2018. Calcif Tissue Int. 103: 625-637. PMID: 30019315
- Exploration of effect of Odanacatib on inhibiting orthodontic recurrence in rats and on CatK and IGF-1 mRNA. | Ye, J., et al. 2019. Eur Rev Med Pharmacol Sci. 23: 3151-3158. PMID: 31081065
Inhibitor of:
8030411F24Rik, Cathepsin, cathepsin 8, cathepsin B, cathepsin J, cathepsin K, cathepsin M, cathepsin Q, cementum attachment protein, CST, cystatin SN, DC-STAMP, Mast Cell Tryptase, PERP (p53 apoptosis effector related to PMP22), POP2, PRC, stefin A2l1, and Vmn1r152.Activator of:
Sgo2, and TCIRG1.Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
Odanacatib, 5 mg | sc-364675 | 5 mg | $218.00 | |||
Odanacatib, 25 mg | sc-364675A | 25 mg | $993.00 | |||
Odanacatib, 250 mg | sc-364675B | 250 mg | $1982.00 |